Drug Profile
Research programme: cardiovascular disease therapies - CliniGenetics
Alternative Names: Nimoxine™Latest Information Update: 02 Feb 2011
Price :
$50
*
At a glance
- Originator CliniGenetics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 18 Sep 2007 Lead compounds are available for licensing (http://www.clinigenetics.com/main_corporate.htm)
- 08 Dec 2003 Preclinical trials in Atherosclerosis in France (unspecified route)
- 08 Dec 2003 Preclinical trials in Cardiovascular disorders in France (unspecified route)